Inducing one week of daily cyclic high fever response during individually dose adapted IL-2 we are in the footsteps of William B. Coley, the father of cancer immunotherapy who administered an FDA-approved fever inducing bacterial inoculate for the treatment of soft tissue sarcomas [50]. Here, IL2 is linked to soft tissue sarcoma.